ADAR1 Capital Management LLC Boosts Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

ADAR1 Capital Management LLC raised its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 212.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 126,792 shares of the company's stock after acquiring an additional 86,158 shares during the quarter. ADAR1 Capital Management LLC owned approximately 0.23% of Voyager Therapeutics worth $719,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock worth $6,316,000 after purchasing an additional 6,740 shares in the last quarter. FMR LLC increased its holdings in shares of Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company's stock worth $541,000 after buying an additional 19,622 shares in the last quarter. Barclays PLC lifted its stake in shares of Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company's stock valued at $612,000 after acquiring an additional 37,398 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock valued at $223,000 after acquiring an additional 7,573 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after acquiring an additional 2,354 shares during the last quarter. Institutional investors own 48.03% of the company's stock.

Insiders Place Their Bets

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the transaction, the chief executive officer now owns 430,931 shares in the company, valued at approximately $1,478,093.33. The trade was a 2.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 15,163 shares of company stock worth $59,158. Corporate insiders own 4.53% of the company's stock.

Voyager Therapeutics Stock Up 6.0 %

Voyager Therapeutics stock traded up $0.18 during trading hours on Friday, reaching $3.17. 313,556 shares of the company's stock were exchanged, compared to its average volume of 461,459. The firm's 50 day simple moving average is $3.95 and its 200 day simple moving average is $5.39. Voyager Therapeutics, Inc. has a twelve month low of $2.75 and a twelve month high of $9.55. The firm has a market capitalization of $175.01 million, a PE ratio of 4.46 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. During the same quarter in the previous year, the firm posted $1.25 earnings per share. Analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on VYGR. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the stock an "overweight" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Voyager Therapeutics has a consensus rating of "Buy" and a consensus target price of $13.97.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.